{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T02:01:00Z","timestamp":1780192860608,"version":"3.54.0"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118920","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:27:00Z","timestamp":1778282820000},"page":"118920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Structural optimization of cholesteryl ester transfer protein inhibitors: From early scaffolds to advanced clinical candidates"],"prefix":"10.1016","volume":"315","author":[{"given":"Mahla","family":"Abdollahzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahin","family":"Ramezani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0782-1907","authenticated-orcid":false,"given":"Mahdi","family":"Hatamipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118920_bib1","first-page":"101992","article-title":"Deciphering the association of cholesteryl ester transfer protein (CETP) gene polymorphisms with high-density lipoprotein cholesterol (HDL-c) levels in the Bangladeshi population","volume":"42","author":"Saiedullah","year":"2025","journal-title":"Biochem. Biophys. Rep."},{"issue":"21","key":"10.1016\/j.ejmech.2026.118920_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031459","article-title":"Genome\u2010wide association study of cardiovascular resilience identifies protective variation in the CETP gene","volume":"12","author":"Yu","year":"2023","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118920_bib3","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/biof.2057","article-title":"Cholesterol transport and beyond: illuminating the versatile functions of HDL apolipoproteins through structural insights and functional implications","volume":"50","author":"Bhale","year":"2024","journal-title":"Biofactors"},{"issue":"18","key":"10.1016\/j.ejmech.2026.118920_bib4","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/jm020038h","article-title":"Chiral N, N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer protein","volume":"45","author":"Durley","year":"2002","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118920_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/ATVBAHA.121.317181","article-title":"Pharmacological inhibition of CETP (cholesteryl ester transfer protein) increases HDL (high-density lipoprotein) that contains ApoC3 and other HDL subspecies associated with higher risk of coronary heart disease","volume":"42","author":"Furtado","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118920_bib6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1194\/jlr.R027011","article-title":"New molecular insights into CETP structure and function: a review","volume":"53","author":"Charles","year":"2012","journal-title":"J. Lipid Res."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118920_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11883-023-01087-1","article-title":"Structure-based mechanism and inhibition of cholesteryl ester transfer protein","volume":"25","author":"Xue","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.ejmech.2026.118920_bib8","series-title":"HDL Metabolism and Diseases","first-page":"13","article-title":"HDL and cholesterol ester transfer protein (CETP)","author":"Deng","year":"2022"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib9","article-title":"HDL and reverse cholesterol transport in humans and animals: lessons from pre-clinical models and clinical studies","volume":"1867","author":"Zanotti","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ejmech.2026.118920_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3389\/fphys.2018.00526","article-title":"Reverse cholesterol transport: molecular mechanisms and the non-medical approach to enhance HDL cholesterol","volume":"9","author":"Marques","year":"2018","journal-title":"Front. Physiol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118920_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2026.118920_bib12","series-title":"Introduction to Lipids and Lipoproteins","author":"Feingold","year":"2024"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118920_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ecl.2022.02.008","article-title":"Lipid and lipoprotein metabolism","volume":"51","author":"Feingold","year":"2022","journal-title":"Endocrinol. Metabol. Clin"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118920_bib14","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1194\/jlr.RA120000691","article-title":"The lipid transfer properties of CETP define the concentration and composition of plasma lipoproteins","volume":"61","author":"Morton","year":"2020","journal-title":"J. Lipid Res."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118920_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100260","article-title":"The cholesteryl ester transfer protein (CETP) raises cholesterol levels in the brain","volume":"63","author":"Oestereich","year":"2022","journal-title":"J. Lipid Res."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118920_bib16","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1194\/jlr.RA120000691","article-title":"The lipid transfer properties of CETP define the concentration and composition of plasma lipoproteins [S]","volume":"61","author":"Morton","year":"2020","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118920_bib17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1194\/jlr.R082735","article-title":"Cholesteryl ester transfer protein and its inhibitors","volume":"59","author":"Shrestha","year":"2018","journal-title":"J. Lipid Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118920_bib18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3390\/life11060581","article-title":"Hyperalphalipoproteinemia and beyond: the role of HDL in cardiovascular diseases","volume":"11","author":"Giammanco","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.ejmech.2026.118920_bib19","series-title":"Exploring the Interplay Between Bile Acids, High-Density Lipoproteins and Endothelial Cells in the Context of Obesity","author":"Dietrich","year":"2024"},{"key":"10.1016\/j.ejmech.2026.118920_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.atherosclerosis.2017.05.028","article-title":"Genetic factors exist behind the high prevalence of reduced high-density lipoprotein cholesterol levels in the Roma population","volume":"263","author":"Pik\u00f3","year":"2017","journal-title":"Atherosclerosis"},{"issue":"14","key":"10.1016\/j.ejmech.2026.118920_bib21","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","article-title":"Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?","volume":"118","author":"Nurmohamed","year":"2022","journal-title":"Cardiovasc. Res."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118920_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological bases for the superiority of apolipoprotein b over low\u2010density lipoprotein cholesterol and non\u2013high\u2010density lipoprotein cholesterol as a marker of cardiovascular risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118920_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/CIRCULATIONAHA.114.014025","article-title":"Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP inhibition as a strategy to reduce cardiovascular risk: the pro case","volume":"132","author":"Barter","year":"2015","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118920_bib24","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ahj.2015.09.007","article-title":"Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial","volume":"170","author":"Nicholls","year":"2015","journal-title":"Am. Heart J."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118920_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2022.4808","article-title":"Cholesteryl ester transfer protein inhibitors and access to the retina in age-related macular degeneration","volume":"8","author":"Curcio","year":"2023","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ejmech.2026.118920_bib26","article-title":"Reducing CETP activity prevents memory decline in an Alzheimer's disease mouse model","author":"Ph\u00e9nix","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2026.118920_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1171937","article-title":"CETP inhibitor evacetrapib enters mouse brain tissue","volume":"14","author":"Ph\u00e9nix","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13024-023-00671-y","article-title":"Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia","volume":"18","author":"Poliakova","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacl.2020.12.007","article-title":"Atherosclerotic cardiovascular disease in hyperalphalipoproteinemia due to LIPG variants","volume":"15","author":"Cole","year":"2021","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ejmech.2026.118920_bib30","series-title":"CETP-related Hyperalphalipoproteinemia","author":"Burnett","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118920_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PGPM.S278671","article-title":"Association of CETP gene variants with atherogenic dyslipidemia among thai patients treated with statin","author":"Srisawasdi","year":"2021","journal-title":"Pharmacogenomics Personalized Med."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118920_bib32","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11883-023-01167-2","article-title":"Obesity and dyslipidemia","volume":"25","author":"Nussbaumerova","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118920_bib33","doi-asserted-by":"crossref","first-page":"zqae024","DOI":"10.1093\/function\/zqae024","article-title":"Sex-specific effects of cholesteryl ester transfer protein (CETP) on the perivascular adipose tissue","volume":"5","author":"Lazaro","year":"2024","journal-title":"Function"},{"issue":"9\u201310","key":"10.1016\/j.ejmech.2026.118920_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.18632\/genesandcancer.122","article-title":"Identification of CETP as a molecular target for estrogen positive breast cancer cell death by cholesterol depleting agents","volume":"7","author":"Esau","year":"2016","journal-title":"Genes Cancer"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118920_bib35","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/iub.2823","article-title":"Cholesteryl ester transfer protein knock\u2010down in conjunction with a cholesterol\u2010depleting agent decreases tamoxifen resistance in breast cancer cells","volume":"76","author":"Gu","year":"2024","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ejmech.2026.118920_bib36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbacli.2017.07.002","article-title":"Antioxidative activity of high-density lipoprotein (HDL): mechanistic insights into potential clinical benefit","volume":"8","author":"Brites","year":"2017","journal-title":"BBA Clin."},{"key":"10.1016\/j.ejmech.2026.118920_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1784014","article-title":"CETP lowers TLR4 expression which attenuates the inflammatory response induced by LPS and polymicrobial sepsis","volume":"2016","author":"Venancio","year":"2016","journal-title":"Mediat. Inflamm."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118920_bib38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nsmb1197","article-title":"Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules","volume":"14","author":"Qiu","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118920_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/prot.24200","article-title":"Structural features of cholesteryl ester transfer protein: a molecular dynamics simulation study","volume":"81","author":"Lei","year":"2013","journal-title":"Proteins: Struct., Funct., Bioinf."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2462466","article-title":"Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention","volume":"21","author":"Hu","year":"2025","journal-title":"Hum. Vaccines Immunother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib41","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11033-025-10537-9","article-title":"Predicted risk genotypes to cardiovascular diseases based on cholesterol ester transfer protein (CETP-rs708272) and lipoprotein lipase (LPL-rs13702) variants in worldwide populations: highest risk in populations with Native American ancestry","volume":"52","author":"Zamudio-Felix","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejmech.2026.118920_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1512670","article-title":"Lipid-lowering effect of combined therapy with high-intensity statins and CETP inhibitors: a systematic review and meta-analysis","volume":"16","author":"Xiang","year":"2025","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2026.118920_bib43","first-page":"1","article-title":"The impact of carbon emissions trading policy on low-carbon economic development in China: an empirical analysis based on the environmental triple effect","author":"Wang","year":"2025","journal-title":"Environ. Dev. Sustain."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118920_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202405697","article-title":"Molecular modeling, cheminformatics analysis, and synthesis of trifluoromethylated aromatic sulfonamides as putative inhibitors of Cholesteryl Ester Transfer protein","volume":"10","author":"Khalaf","year":"2025","journal-title":"ChemistrySelect"},{"issue":"15","key":"10.1016\/j.ejmech.2026.118920_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512252","article-title":"Dissecting the structural dynamics of authentic Cholesteryl Ester Transfer protein for the discovery of potential lead compounds: a theoretical study","volume":"24","author":"Zhao","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118920_bib46","series-title":"The Molecular Basis of Positional Information in Salamander Limb Regeneration","author":"Polvadore","year":"2021"},{"key":"10.1016\/j.ejmech.2026.118920_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12918-019-0679-x","article-title":"A mathematical model to estimate cholesterylester transfer protein (CETP) triglycerides flux in human plasma","volume":"13","author":"Jansen","year":"2019","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.ejmech.2026.118920_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2023.107093","article-title":"Structural insights on the deformations induced by various mutations on cholesteryl ester transfer protein","volume":"301","author":"Revanasiddappa","year":"2023","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.ejmech.2026.118920_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ibiod.2024.105992","article-title":"Optimizing biodegradation of polychlorinated biphenyls (PCBs) using bacteria isolated from common effluent treatment plant (CETP) sludge: integration of machine learning, kinetic studies, and metabolomic analysis","volume":"198","author":"Thathola","year":"2025","journal-title":"Int. Biodeterior. Biodegrad."},{"key":"10.1016\/j.ejmech.2026.118920_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.scs.2024.105955","article-title":"Synergistic impacts of carbon emission trading policy and innovative city pilot policy on urban land green use efficiency in China","volume":"118","author":"Zhang","year":"2025","journal-title":"Sustain. Cities Soc."},{"key":"10.1016\/j.ejmech.2026.118920_bib51","first-page":"RV22037","article-title":"Cholesteryl ester transfer protein deficiency and hyperalphalipoproteinemia","author":"Inazu","year":"2025","journal-title":"J. Atheroscler Thromb."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118920_bib52","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2174\/0113816128284695240219093612","article-title":"Cholesteryl ester transfer protein (CETP) variations in relation to lipid profiles and cardiovascular diseases: an update","volume":"30","author":"Dabravolski","year":"2024","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib53","doi-asserted-by":"crossref","first-page":"8741","DOI":"10.1038\/srep08741","article-title":"HDL surface lipids mediate CETP binding as revealed by electron microscopy and molecular dynamics simulation","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118920_bib54","series-title":"Molecular Insights into Macromolecules Structure, Function, and Regulation","first-page":"5296","author":"Yang","year":"2024"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118920_bib55","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2174\/0113852728295939240315040152","article-title":"Synthesis and In-Silico studies of ortho-fluorinated benzenesulfonamides as putative Anti-CETP agents","volume":"28","author":"Abu Khalaf","year":"2024","journal-title":"Curr. Org. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118920_bib56","doi-asserted-by":"crossref","first-page":"60","DOI":"10.56557\/upjoz\/2024\/v45i204565","article-title":"In silico docking studies between atorvastatin and human cholesteryl ester transfer protein (CETP) facilitating the conversion of triglycerides found in VLDL into cholesterol esters found in HDL of pan troglodytes","volume":"45","author":"Sathya","year":"2024","journal-title":"Uttar Pradesh J. Zool."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13065-024-01192-5","article-title":"Discovery of novel cholesteryl ester transfer protein (CETP) inhibitors by a multi-stage virtual screening","volume":"18","author":"Liu","year":"2024","journal-title":"BMC Chem."},{"issue":"37","key":"10.1016\/j.ejmech.2026.118920_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202403288","article-title":"Synthesis, molecular modeling, and evaluation of novel methylated benzene sulfonamide derivatives as cholesteryl ester transfer protein (CETP) inhibitors","volume":"9","author":"Khalaf","year":"2024","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.ejmech.2026.118920_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.858137","article-title":"Discovery of a potent and orally active dual GPBAR1\/CysLT1R modulator for the treatment of metabolic fatty liver disease","volume":"13","author":"Fiorucci","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118920_bib60","series-title":"Influence of Lipoproteins and Lipid Transfer in Copolymer Micelle Instability","author":"Langridge","year":"2021"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118920_bib61","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3390\/ijms18061260","article-title":"The therapeutic potential of anti-inflammatory exerkines in the treatment of atherosclerosis","volume":"18","author":"Yu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"A","key":"10.1016\/j.ejmech.2026.118920_bib62","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3889\/oamjms.2022.10457","article-title":"New cholesteryl ester transfer protein from Indonesian herbal plants as candidate treatment of cardiovascular disease","volume":"10","author":"Yudhani","year":"2022","journal-title":"Open Access Maced. J. Med. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118920_bib63","doi-asserted-by":"crossref","first-page":"777","DOI":"10.14348\/molcells.2014.0265","article-title":"Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors","volume":"37","author":"Mabuchi","year":"2014","journal-title":"Mol. Cells"},{"issue":"21","key":"10.1016\/j.ejmech.2026.118920_bib64","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118920_bib65","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib\u2010induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118920_bib66","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118920_bib67","doi-asserted-by":"crossref","unstructured":"Barter Philip, J., et al., Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21): p. 2109\u20132122.","DOI":"10.1056\/NEJMoa0706628"},{"issue":"22","key":"10.1016\/j.ejmech.2026.118920_bib68","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118920_bib69","first-page":"372","article-title":"Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib","volume":"8","author":"Tardif","year":"2015","journal-title":"Circulation: Cardiovasc. Gene."},{"issue":"9802","key":"10.1016\/j.ejmech.2026.118920_bib70","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118920_bib71","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/eurheartj\/ehs019","article-title":"Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial","volume":"33","author":"L\u00fcscher","year":"2012","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.ejmech.2026.118920_bib72","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118920_bib73","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118920_bib74","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Group","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118920_bib75","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2125.2009.03465.x","article-title":"Single\u2010dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects","volume":"68","author":"Krishna","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"25","key":"10.1016\/j.ejmech.2026.118920_bib76","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ejmech.2026.118920_bib77","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.ejmech.2026.118920_bib78","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100316","article-title":"Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans","volume":"64","author":"Brodeur","year":"2023","journal-title":"J. Lipid Res."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118920_bib80","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/17576180.2024.2376427","article-title":"Quantitation of anacetrapib in human and animal adipose by liquid chromatography with mass spectrometric detection","volume":"16","author":"Fang","year":"2024","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ejmech.2026.118920_bib81","article-title":"CETP inhibition reduces cardiovascular events by lowering of cumulative LDL exposure: reconciling evidence from human genetics and clinical trials","author":"Landfors","year":"2024","journal-title":"medRxiv"},{"issue":"13","key":"10.1016\/j.ejmech.2026.118920_bib82","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118920_bib83","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bcp.12380","article-title":"Tolerability, pharmacokinetics and pharmacodynamics of TA\u20108995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects","volume":"78","author":"Ford","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118920_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70010","article-title":"Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: an integrated summary of results from non\u2010human primate studies and clinical trials","volume":"12","author":"Nicholls","year":"2024","journal-title":"Pharmacol. Res. Perspect."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118920_bib85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11883-023-01184-1","article-title":"Obicetrapib: reversing the tide of CETP inhibitor disappointments","volume":"26","author":"Kastelein","year":"2024","journal-title":"Curr. Atheroscler. Rep."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118920_bib86","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11883-024-01231-5","article-title":"Obicetrapib\u2014The rebirth of CETP inhibitors?","volume":"26","author":"Chang","year":"2024","journal-title":"Curr. Atheroscler. Rep."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118920_bib87","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.5551\/jat.ED265","article-title":"Obicetrapib: there is still life in the CETP inhibitor","volume":"31","author":"Ogura","year":"2024","journal-title":"J. Atheroscler Thromb."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118920_bib88","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jacl.2024.12.016","article-title":"Lipid-lowering efficacy of obicetrapib: a comprehensive systematic review and meta-analysis","volume":"19","author":"Masson","year":"2025","journal-title":"J. Clin. Lipidol."},{"issue":"18","key":"10.1016\/j.ejmech.2026.118920_bib89","doi-asserted-by":"crossref","first-page":"13215","DOI":"10.1021\/acs.jmedchem.1c00959","article-title":"Invention of MK-8262, a cholesteryl ester transfer protein (CETP) inhibitor backup to anacetrapib with best-in-class properties","volume":"64","author":"Vachal","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib90","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118920_bib91","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1021\/jm020528+","article-title":"Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein","volume":"46","author":"Reinhard","year":"2003","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118920_bib92","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1021\/jm000337b","article-title":"Discovery of chiral N, N-disubstituted trifluoro-3-amino-2-propanols as potent inhibitors of cholesteryl ester transfer protein","volume":"43","author":"Durley","year":"2000","journal-title":"J. Med. Chem."},{"issue":"45","key":"10.1016\/j.ejmech.2026.118920_bib93","doi-asserted-by":"crossref","first-page":"13870","DOI":"10.1021\/bi001356q","article-title":"Stereospecific inhibition of CETP by chiral N, N-disubstituted trifluoro-3-amino-2-propanols","volume":"39","author":"Connolly","year":"2000","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118920_bib94","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1021\/jm801319d","volume":"52","author":"Kuo","year":"2009","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118920_bib95","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.bmcl.2009.03.051","article-title":"Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1, 2, 3, 4-tetrahydroquinoline platform","volume":"19","author":"Rano","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118920_bib96","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.bmcl.2009.12.096","article-title":"Synthesis and discovery of 2, 3-dihydro-3, 8-diphenylbenzo [1, 4] oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors","volume":"20","author":"Wang","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118920_bib97","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1021\/acsmedchemlett.5b00404","article-title":"Discovery of novel indoline cholesterol ester transfer protein inhibitors (CETP) through a structure-guided approach","volume":"7","author":"Wilson","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118920_bib98","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1021\/ml100309n","article-title":"Discovery of substituted biphenyl oxazolidinone inhibitors of cholesteryl ester transfer protein","volume":"2","author":"Thompson","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118920_bib99","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1021\/jm200484c","article-title":"Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib","volume":"54","author":"Smith","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118920_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127668","article-title":"Cholesteryl ester transfer protein (CETP) inhibitors based on cyclic urea, bicyclic urea and bicyclic sulfamide cores","volume":"32","author":"Liu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"18","key":"10.1016\/j.ejmech.2026.118920_bib101","doi-asserted-by":"crossref","first-page":"13215","DOI":"10.1021\/acs.jmedchem.1c00959","article-title":"Invention of MK-8262, a cholesteryl ester transfer protein (CETP) inhibitor backup to anacetrapib with best-in-class properties","volume":"64","author":"Vachal","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib102","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bmcl.2011.11.039","article-title":"SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors","volume":"22","author":"Lu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118920_bib103","series-title":"Fused Bicyclic Oxazolidinone CETP Inhibitor","author":"Shao","year":"2016"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118920_bib104","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.bmcl.2008.03.030","article-title":"2-Arylbenzoxazoles as novel cholesteryl ester transfer protein inhibitors: optimization via array synthesis","volume":"18","author":"Harikrishnan","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118920_bib105","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.bmcl.2009.12.046","article-title":"2-Arylbenzoxazoles as CETP inhibitors: substitution and modification of the \u03b1-alkoxyamide moiety","volume":"20","author":"Hunt","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib106","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.bmcl.2010.10.062","article-title":"2-Arylbenzoxazoles as CETP inhibitors: raising HDL-C in cynoCETP transgenic mice","volume":"21","author":"Kallashi","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118920_bib107","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.bmcl.2011.02.049","article-title":"2-(4-Carbonylphenyl) benzoxazole inhibitors of CETP: attenuation of hERG binding and improved HDLc-raising efficacy","volume":"21","author":"Sweis","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"24","key":"10.1016\/j.ejmech.2026.118920_bib108","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1016\/j.bmcl.2010.10.019","article-title":"Design of a novel class of biphenyl CETP inhibitors","volume":"20","author":"Lu","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118920_bib109","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejmech.2016.07.065","article-title":"Design, synthesis and biological evaluation of novel cholesteryl ester transfer protein inhibitors bearing a cycloalkene scaffold","volume":"123","author":"Liu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118920_bib110","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1021\/jm300611v","article-title":"Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors","volume":"55","author":"Harikrishnan","year":"2012","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118920_bib111","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1016\/j.bmcl.2012.08.011","article-title":"Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors","volume":"22","author":"Miller","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"14","key":"10.1016\/j.ejmech.2026.118920_bib112","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1016\/j.bmcl.2016.05.058","article-title":"Discovery of hydroxyl 1, 2-diphenylethanamine analogs as potent cholesterol ester transfer protein inhibitors","volume":"26","author":"Jiang","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118920_bib113","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1021\/acsmedchemlett.9b00086","article-title":"Discovery of a lead triphenylethanamine cholesterol ester transfer protein (CETP) inhibitor","volume":"10","author":"Finlay","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118920_bib114","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejmech.2016.09.098","article-title":"Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors","volume":"126","author":"Chang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118920_bib115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejmech.2017.08.012","article-title":"Discovery of pentacyclic triterpene 3\u03b2-ester derivatives as a new class of cholesterol ester transfer protein inhibitors","volume":"139","author":"Chen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118920_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126824","article-title":"Synthesis, biological evaluation and SAR studies of ursolic acid 3\u03b2-ester derivatives as novel CETP inhibitors","volume":"30","author":"Chen","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118920_bib117","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bmc.2015.12.010","article-title":"Design, synthesis and biological evaluation of N, N-3-phenyl-3-benzylaminopropanamide derivatives as novel cholesteryl ester transfer protein inhibitor","volume":"24","author":"Zhao","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118920_bib118","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.bmc.2016.03.002","article-title":"Discovery of novel N, N-3-phenyl-3-benzylaminopropionanilides as potent inhibitors of cholesteryl ester transfer protein in vivo","volume":"24","author":"Xie","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118920_bib119","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3390\/molecules22111925","article-title":"Design, synthesis, and biological evaluation of N, N-disubstituted-4-arylthiazole-2-methylamine derivatives as cholesteryl ester transfer inhibitors","volume":"22","author":"Wang","year":"2017","journal-title":"Molecules"},{"issue":"21","key":"10.1016\/j.ejmech.2026.118920_bib120","doi-asserted-by":"crossref","first-page":"8766","DOI":"10.1021\/jm500431d","article-title":"Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1, 1\u2032-spiro-substituted hexahydrofuroquinoline derivatives","volume":"57","author":"Trieselmann","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118920_bib121","series-title":"Substituted Pyridine Compound","author":"Nakamura","year":"2015"},{"issue":"15","key":"10.1016\/j.ejmech.2026.118920_bib122","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.bmcl.2005.05.073","article-title":"Dibenzodioxocinones\u2014A new class of CETP inhibitors","volume":"15","author":"Br\u00fcckner","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"20","key":"10.1016\/j.ejmech.2026.118920_bib123","doi-asserted-by":"crossref","first-page":"8466","DOI":"10.1021\/acs.jmedchem.7b00900","article-title":"Discovery of a novel piperidine-based inhibitor of cholesteryl ester transfer protein (CETP) that retains activity in hypertriglyceridemic plasma","volume":"60","author":"Yamada","year":"2017","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118920_bib124","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1016\/j.bmcl.2012.03.075","article-title":"Design, synthesis and structure\u2013activity-relationship of 1, 5-tetrahydronaphthyridines as CETP inhibitors","volume":"22","author":"Fernandez","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118920_bib125","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.bmcl.2007.01.112","article-title":"Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors","volume":"17","author":"Eary","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118920_bib126","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1016\/j.bmcl.2012.04.042","article-title":"Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors","volume":"22","author":"Escribano","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"19","key":"10.1016\/j.ejmech.2026.118920_bib127","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1021\/jm000224s","article-title":"bis(2-(Acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein","volume":"43","author":"Shinkai","year":"2000","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118920_bib128","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.bmcl.2004.02.071","article-title":"S-(2-(Acylamino) phenyl) 2, 2-dimethylpropanethioates as CETP inhibitors","volume":"14","author":"Maeda","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118920_bib129","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ahj.2024.05.002","article-title":"Obicetrapib on top of maximally tolerated lipid\u2010modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN","volume":"274","author":"Nicholls","year":"2024","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib130","doi-asserted-by":"crossref","DOI":"10.1007\/s15027-025-3727-z","article-title":"Etabliert sich ein CETP-Hemmer als LDL-Senker?","volume":"25","author":"Einecke","year":"2025","journal-title":"Cardiovasc"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118920_bib131","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamacardio.2022.2333","article-title":"Joint genetic inhibition of PCSK9 and CETP and the association with coronary artery disease: a factorial Mendelian randomization study","volume":"7","author":"Cupido","year":"2022","journal-title":"JAMA Cardiol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118920_bib132","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clinthera.2021.12.005","article-title":"Efficacy and safety of PCSK9 monoclonal antibodies in patients with diabetes","volume":"44","author":"Marouf","year":"2022","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejmech.2026.118920_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122823","article-title":"Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: potential targets for natural products in managing hypercholesterolemia","author":"Aguchem","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2026.118920_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105524","article-title":"Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE\u2217 3-Leiden. CETP mice","volume":"167","author":"Zhou","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118920_bib135","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.32604\/biocell.2023.031063","article-title":"High density lipoprotein as a therapeutic target: focus on its functionality","volume":"47","author":"G\u00f3mez Rosso","year":"2023","journal-title":"Biocell"},{"issue":"24","key":"10.1016\/j.ejmech.2026.118920_bib136","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018136","article-title":"Effect of anacetrapib on cholesterol efflux capacity: a substudy of the DEFINE trial","volume":"9","author":"Metzinger","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejmech.2026.118920_bib137","series-title":"Nutrition, Nutraceuticals and Bioactive Compounds in the Prevention and Fight Against Inflammation","first-page":"2629","author":"Surma","year":"2023"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118920_bib138","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ygeno.2020.11.009","article-title":"Repurposed drugs and nutraceuticals targeting envelope protein: a possible therapeutic strategy against COVID-19","volume":"113","author":"Das","year":"2021","journal-title":"Genomics"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600365X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600365X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T01:29:52Z","timestamp":1780190992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342600365X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":138,"alternative-id":["S022352342600365X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118920","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural optimization of cholesteryl ester transfer protein inhibitors: From early scaffolds to advanced clinical candidates","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118920"}}